Is DBRG or BBOT more profitable?

DigitalBridge Group's return on equity of 3.89% beat BridgeBio Oncology Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DigitalBridge Group N/A 3.89% 1.86% BridgeBio Oncology Therapeutics N/A N/A N/A

Does the media refer more to DBRG or BBOT?

In the previous week, BridgeBio Oncology Therapeutics had 6 more articles in the media than DigitalBridge Group. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 2 mentions for DigitalBridge Group. DigitalBridge Group's average media sentiment score of 0.30 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that DigitalBridge Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DigitalBridge Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to UNIT or BBOT?

In the previous week, BridgeBio Oncology Therapeutics had 5 more articles in the media than Uniti Group. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Uniti Group. Uniti Group's average media sentiment score of 0.25 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Uniti Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Uniti Group 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BridgeBio Oncology Therapeutics (BBOT) Competitors

$7.81 -0.42 (-5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$7.82 +0.01 (+0.06%)

As of 07:32 PM Eastern

Compare

BBOT vs. DBRG, FCPT, UNIT, IVT, and AAMI

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? MarketBeat compares BridgeBio Oncology Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Oncology Therapeutics include DigitalBridge Group (DBRG), Four Corners Property Trust (FCPT), Uniti Group (UNIT), InvenTrust Properties (IVT), and Acadian Asset Management (AAMI). These companies are all part of the "trading" industry.

How does BridgeBio Oncology Therapeutics compare to DigitalBridge Group?

DigitalBridge Group (NYSE:DBRG) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both trading companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

DigitalBridge Group has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than DigitalBridge Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DigitalBridge Group	$374.45M	7.63	$141.87M	$0.49	31.97
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

92.7% of DigitalBridge Group shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 3.4% of DigitalBridge Group shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

DigitalBridge Group has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

DigitalBridge Group's return on equity of 3.89% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DigitalBridge Group	N/A	3.89%	1.86%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

In the previous week, BridgeBio Oncology Therapeutics had 6 more articles in the media than DigitalBridge Group. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 2 mentions for DigitalBridge Group. DigitalBridge Group's average media sentiment score of 0.30 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that DigitalBridge Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DigitalBridge Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DigitalBridge Group currently has a consensus price target of $16.00, suggesting a potential upside of 2.14%. BridgeBio Oncology Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 220.10%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than DigitalBridge Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DigitalBridge Group	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

DigitalBridge Group beats BridgeBio Oncology Therapeutics on 9 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Four Corners Property Trust?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Four Corners Property Trust (NYSE:FCPT) are both trading companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of Four Corners Property Trust shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Four Corners Property Trust shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 220.10%. Four Corners Property Trust has a consensus target price of $28.13, indicating a potential upside of 13.96%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Four Corners Property Trust.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Four Corners Property Trust	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

Four Corners Property Trust has a net margin of 38.74% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. Four Corners Property Trust's return on equity of 7.38% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Four Corners Property Trust	38.74%	7.38%	4.06%

In the previous week, BridgeBio Oncology Therapeutics had 2 more articles in the media than Four Corners Property Trust. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 6 mentions for Four Corners Property Trust. Four Corners Property Trust's average media sentiment score of 1.11 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Four Corners Property Trust is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Four Corners Property Trust	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Oncology Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Four Corners Property Trust has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Four Corners Property Trust has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Four Corners Property Trust, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Four Corners Property Trust	$294.13M	9.21	$112.36M	$1.12	22.03

Summary

Four Corners Property Trust beats BridgeBio Oncology Therapeutics on 10 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Uniti Group?

Uniti Group (NASDAQ:UNIT) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both trading companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Uniti Group has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, BridgeBio Oncology Therapeutics had 5 more articles in the media than Uniti Group. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Uniti Group. Uniti Group's average media sentiment score of 0.25 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Uniti Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Uniti Group	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Uniti Group has a net margin of 39.61% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Uniti Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Uniti Group	39.61%	-2.52%	-3.44%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

Uniti Group has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Uniti Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Uniti Group	$2.23B	1.27	$1.30B	$3.35	3.49
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

Uniti Group presently has a consensus target price of $10.92, indicating a potential downside of 6.54%. BridgeBio Oncology Therapeutics has a consensus target price of $25.00, indicating a potential upside of 220.10%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Uniti Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Uniti Group	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

87.5% of Uniti Group shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 2.7% of Uniti Group shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Uniti Group beats BridgeBio Oncology Therapeutics on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to InvenTrust Properties?

InvenTrust Properties (NYSE:IVT) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

InvenTrust Properties currently has a consensus target price of $34.17, suggesting a potential upside of 2.08%. BridgeBio Oncology Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 220.10%. Given BridgeBio Oncology Therapeutics' higher probable upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than InvenTrust Properties.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InvenTrust Properties	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

InvenTrust Properties has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

InvenTrust Properties has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than InvenTrust Properties, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InvenTrust Properties	$299.17M	8.72	$111.42M	$1.41	23.74
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

61.7% of InvenTrust Properties shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 0.7% of InvenTrust Properties shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Oncology Therapeutics had 7 more articles in the media than InvenTrust Properties. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 1 mentions for InvenTrust Properties. InvenTrust Properties' average media sentiment score of 0.40 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that InvenTrust Properties is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InvenTrust Properties	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InvenTrust Properties has a net margin of 35.66% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. InvenTrust Properties' return on equity of 6.10% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InvenTrust Properties	35.66%	6.10%	3.95%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

Summary

InvenTrust Properties beats BridgeBio Oncology Therapeutics on 12 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Acadian Asset Management?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Acadian Asset Management (NYSE:AAMI) are both trading companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

In the previous week, BridgeBio Oncology Therapeutics had 6 more articles in the media than Acadian Asset Management. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 2 mentions for Acadian Asset Management. Acadian Asset Management's average media sentiment score of 1.56 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Acadian Asset Management is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acadian Asset Management	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Acadian Asset Management has a net margin of 13.78% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. Acadian Asset Management's return on equity of 185.73% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Acadian Asset Management	13.78%	185.73%	19.17%

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Acadian Asset Management shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 22.6% of Acadian Asset Management shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BridgeBio Oncology Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Acadian Asset Management has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

BridgeBio Oncology Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 220.10%. Acadian Asset Management has a consensus price target of $62.00, suggesting a potential downside of 16.09%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Acadian Asset Management.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Acadian Asset Management	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Acadian Asset Management has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Acadian Asset Management, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Acadian Asset Management	$563.70M	4.67	$80M	$2.35	31.44

Summary

Acadian Asset Management beats BridgeBio Oncology Therapeutics on 10 of the 15 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBOT vs. The Competition

Export

Metric	BridgeBio Oncology Therapeutics	Investment Offices Industry	Financial Sector	NASDAQ Exchange
Market Cap	$659.28M	$331.77M	$5.73B	$12.46B
Dividend Yield	N/A	N/A	5.28%	5.34%
P/E Ratio	-3.81	2.22	16.37	23.64
Price / Sales	N/A	198.47	1,111.82	112.53
Price / Cash	N/A	137.89	91.78	57.17
Price / Book	1.52	347.58	6.49	6.37
Net Income	-$134.04M	-$66.73M	$1.14B	$337.36M
7 Day Performance	-12.93%	-0.12%	-0.75%	-3.07%
1 Month Performance	-5.56%	3.38%	0.92%	0.37%
1 Year Performance	N/A	8.50%	19.07%	27.87%

BridgeBio Oncology Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBOT BridgeBio Oncology Therapeutics	1.7419 of 5 stars	$7.81 -5.1%	$25.00 +220.1%	N/A	$659.28M	N/A	N/A	N/A	News Coverage
DBRG DigitalBridge Group	0.9884 of 5 stars	$15.68 -0.2%	$16.00 +2.1%	+42.0%	$2.86B	$374.45M	31.99	300
FCPT Four Corners Property Trust	4.3134 of 5 stars	$24.96 -0.3%	$28.00 +12.2%	-12.6%	$2.74B	$294.13M	22.29	540	Positive News Analyst Downgrade
UNIT Uniti Group	1.6427 of 5 stars	$11.22 -1.8%	$10.92 -2.7%	+172.9%	$2.72B	$2.23B	3.35	8,632
IVT InvenTrust Properties	2.5178 of 5 stars	$33.19 -0.1%	$34.17 +3.0%	+18.3%	$2.59B	$299.17M	23.54	110	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. DBRG, FCPT, UNIT, IVT, and AAMI

How does BridgeBio Oncology Therapeutics compare to DigitalBridge Group?

Summary

How does BridgeBio Oncology Therapeutics compare to Four Corners Property Trust?

Summary

How does BridgeBio Oncology Therapeutics compare to Uniti Group?

Summary

How does BridgeBio Oncology Therapeutics compare to InvenTrust Properties?

Summary

How does BridgeBio Oncology Therapeutics compare to Acadian Asset Management?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. DBRG, FCPT, UNIT, IVT, and AAMI

How does BridgeBio Oncology Therapeutics compare to DigitalBridge Group?

Which has higher valuation and earnings, DBRG or BBOT?

Do insiders & institutionals hold more shares of DBRG or BBOT?

Which has more volatility and risk, DBRG or BBOT?

Is DBRG or BBOT more profitable?

Does the media refer more to DBRG or BBOT?

Do analysts recommend DBRG or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Four Corners Property Trust?

Do institutionals and insiders believe in BBOT or FCPT?

Do analysts recommend BBOT or FCPT?

Is BBOT or FCPT more profitable?

Does the media favor BBOT or FCPT?

Which has more risk & volatility, BBOT or FCPT?

Which has better valuation & earnings, BBOT or FCPT?

Summary

How does BridgeBio Oncology Therapeutics compare to Uniti Group?

Which has more volatility & risk, UNIT or BBOT?

Does the media refer more to UNIT or BBOT?

Is UNIT or BBOT more profitable?

Which has stronger valuation & earnings, UNIT or BBOT?

Do analysts prefer UNIT or BBOT?

Do insiders & institutionals have more ownership in UNIT or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to InvenTrust Properties?

Do analysts recommend IVT or BBOT?

Which has more volatility & risk, IVT or BBOT?

Which has better valuation and earnings, IVT or BBOT?

Do insiders and institutionals hold more shares of IVT or BBOT?

Does the media favor IVT or BBOT?

Is IVT or BBOT more profitable?

Summary

How does BridgeBio Oncology Therapeutics compare to Acadian Asset Management?

Does the media favor BBOT or AAMI?

Is BBOT or AAMI more profitable?

Do insiders & institutionals have more ownership in BBOT or AAMI?

Which has more risk & volatility, BBOT or AAMI?

Do analysts rate BBOT or AAMI?

Which has better earnings and valuation, BBOT or AAMI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools